Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 6:15:1406351.
doi: 10.3389/fphar.2024.1406351. eCollection 2024.

History of trastuzumab: a case study in health technology reassessment and natural disinvestment in Veneto Region

Antonella Giorgia Becchetti  1 , Anna Martini  2   3 , Giovanna Scroccaro  3 , Roberta Joppi  1   3
Affiliations

History of trastuzumab: a case study in health technology reassessment and natural disinvestment in Veneto Region

Antonella Giorgia Becchetti et al. Front Pharmacol. .
No abstract available

Keywords: biosimilar adoption and commercialization; disinvestment; health technology assessment (HTA); health technology reassessment (HTR); pharmaceutical governance; pharmacoeconomics; real-world data; trastuzumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Monthly (%) percentage of trastuzumab across different domains, covering the period from January 2019 to December 2023. (A) Net NHS expenditure each ATC code: L01FD01 trastuzumab, L01FD03 trastuzumab emtansine, L01FD04 trastuzumab deruxtecan, L01FY01 pertuzumab-trastuzumab; (B) Number of dispensed packages each ATC code: L01FD01 trastuzumab, L01FD03 trastuzumab emtansine, L01FD04 trastuzumab deruxtecan, L01FY01 pertuzumab-trastuzumab; (C) Number of patients treated with formulations of trastuzumab under ATC codes: L01FD01 trastuzumab, L01FD03 trastuzumab emtansine, L01FD04 trastuzumab deruxtecan, L01FY01 pertuzumab-trastuzumab; (D) Net NHS expenditure for different formulations of trastuzumab (ATC code L01FD01): originator IV, biosimilar IV, and originator SC; (E) Number of dispensed packages for different formulations of trastuzumab (ATC code L01FD01): originator IV, biosimilar IV, and originator SC; (F) Number of patients treated with different formulations of trastuzumab (ATC code L01FD01) originator IV, biosimilar IV, and originator SC.
FIGURE 2
FIGURE 2
Monthly expenditure (A), number of packages (B), and number of patients treated (C) with different trastuzumab types or combination (trastuzumab – L01FD01; trastuzumab emtansine – L01FD03; trastuzumab deruxtecan – L01FD04; pertuzumab-trastuzumab – L01FY01).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. AIRTUM (2023). AIRTUM (Associazione Italiana Registri Tumori) I numeri del cancro in Italia 2023.
    1. Albanell J., Codony J., Rovira A., Mellado B., Gascón P. (2003). Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv. Exp. Med. Biol. 532, 253–268. 10.1007/978-1-4615-0081-0_21 - DOI - PubMed
    1. Bardia A., Viale G. (2023). HER2-Low breast cancer-diagnostic challenges and opportunities for insights from ongoing studies: a podcast. Target. Oncol. 18 (3), 313–319. 10.1007/s11523-023-00964-8 - DOI - PMC - PubMed
    1. Barok M., Joensuu H., Isola J. (2014). Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 16 (2), 209. 10.1186/bcr3621 - DOI - PMC - PubMed
    1. Bartsch R. (2020). Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer. Expert Opin. Investigational Drugs 29 (9), 901–910. 10.1080/13543784.2020.1792443 - DOI - PubMed

LinkOut - more resources